98 related articles for article (PubMed ID: 27077771)
61. Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia.
Gu D; Chen Z; Zhao H; Du W; Xue F; Ge J; Sui T; Wu H; Liu B; Lu S; Zhang L; Yang R
Hum Immunol; 2010 Jun; 71(6):586-91. PubMed ID: 20153790
[TBL] [Abstract][Full Text] [Related]
62. Mitochondrial ROS-dependent CD4
Li W; Bai Z; Liu J; Tang Y; Yin C; Jin M; Mu L; Li X
Int Immunopharmacol; 2023 Sep; 122():110597. PubMed ID: 37413931
[TBL] [Abstract][Full Text] [Related]
63. Preliminary Investigation about the Expression of G Protein-Coupled Receptors in Platelets from Patients with Chronic Immune Thrombocytopenic Purpura.
Xu D; Xie L; Zhang Z; Wang D; Qiu J; Yu W; Xu C; He C; Xu X; Yin J
Acta Haematol; 2021; 144(5):551-559. PubMed ID: 33849009
[TBL] [Abstract][Full Text] [Related]
64. Cytotoxic T lymphocyte antigen-4 (CTLA-4) A49G polymorphism and autoimmune blood diseases.
Aktürk F; Hançer VS; Küçükkaya R
Turk J Haematol; 2010 Jun; 27(2):78-81. PubMed ID: 27263448
[TBL] [Abstract][Full Text] [Related]
65. Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs.
Derakhshani A; Asadzadeh Z; Safarpour H; Leone P; Shadbad MA; Heydari A; Baradaran B; Racanelli V
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442365
[TBL] [Abstract][Full Text] [Related]
66. sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis.
Chen Y; Li M; Liu J; Pan T; Zhou T; Liu Z; Tan R; Wang X; Tian L; Chen E; Qu H
Scand J Immunol; 2017 Aug; 86(2):100-106. PubMed ID: 28513984
[TBL] [Abstract][Full Text] [Related]
67. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP).
El Demerdash DM; Saber MM; Ayad A; Gomaa K; Abdelkader Morad M
Blood Res; 2024 Mar; 59(1):8. PubMed ID: 38485815
[TBL] [Abstract][Full Text] [Related]
68. Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity.
Rabenhorst A; Leja S; Schwaab J; Gehring M; Förster A; Arock M; Reiter A; Raap U; Hartmann K
J Allergy Clin Immunol; 2016 Jan; 137(1):314-318.e5. PubMed ID: 26299988
[No Abstract] [Full Text] [Related]
69. Expression of Recombinant CTLA-4 and PD-L1 Proteins Fused with Thioredoxin, and Determination of Their Ligand-Binding Activities.
Zhansaya A; Malika N; Boris D; Kanat T; Kanatbek M; Yerlan R; Kasym M
Rep Biochem Mol Biol; 2022 Jul; 11(2):310-319. PubMed ID: 36164623
[TBL] [Abstract][Full Text] [Related]
70. Correction: Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
Cancer Immunol Res; 2018 Apr; 6(4):498-499. PubMed ID: 29559478
[No Abstract] [Full Text] [Related]
71. [Not Available].
Arerugi; 2019; 68(3):155-156. PubMed ID: 31105112
[No Abstract] [Full Text] [Related]
72. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.
Hong S; Chen N; Fang W; Zhan J; Liu Q; Kang S; He X; Liu L; Zhou T; Huang J; Chen Y; Qin T; Zhang Y; Ma Y; Yang Y; Zhao Y; Huang Y; Zhang L
Oncoimmunology; 2016 Mar; 5(3):e1094598. PubMed ID: 27141355
[TBL] [Abstract][Full Text] [Related]
73. Percentages of PD-1
Wang Y; Pang N; Wang X; Liu Y; Wang X; Wang L; Sun M; Yasen H; Zhao F; Fan W; Guo X; Ding J
Hum Vaccin Immunother; 2018 Apr; 14(4):832-838. PubMed ID: 29333980
[TBL] [Abstract][Full Text] [Related]
74. Abnormal miR-214/A20 expression might play a role in T cell activation in patients with aplastic anemia.
Yu Z; Chen C; Xiao Y; Chen X; Guo L; Tan G; Huang G; Luo W; Zhou M; Li Y; Lin C; Shen Q; Zhang Y; Li B
Blood Sci; 2020 Jul; 2(3):100-105. PubMed ID: 35402824
[TBL] [Abstract][Full Text] [Related]
75. Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer.
Karsono R; Azhar MA; Pratiwi Y; Saputra F; Nadliroh S; Aryandono T
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2069-2077. PubMed ID: 34319029
[TBL] [Abstract][Full Text] [Related]
76. Imbalance of T Lymphocyte Subsets in Adult Immune Thrombocytopenia.
Lin X; Xu A; Zhou L; Zhao N; Zhang X; Xu J; Feng S; Zheng C
Int J Gen Med; 2021; 14():937-947. PubMed ID: 33776472
[TBL] [Abstract][Full Text] [Related]
77. Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction
Han P; Yu T; Hou Y; Zhao Y; Liu Y; Sun Y; Wang H; Xu P; Li G; Sun T; Hu X; Liu X; Li L; Peng J; Zhou H; Hou M
Front Immunol; 2021; 12():630693. PubMed ID: 33679776
[TBL] [Abstract][Full Text] [Related]
78. Lower T cell inhibitory receptor level in mononuclear cells from cord blood compared with peripheral blood.
Lin Y; Lin J; Huang J; Chen Y; Tan J; Li Y; Chen S
Stem Cell Investig; 2019; 6():35. PubMed ID: 31728384
[TBL] [Abstract][Full Text] [Related]
79. Indirubin modulates CD4
Zhao Y; Han P; Liu L; Wang X; Xu P; Wang H; Yu T; Sun Y; Li L; Sun T; Liu X; Zhou H; Qiu J; Wang L; Peng J; Xu S; Hou M
J Cell Mol Med; 2019 Mar; 23(3):1885-1898. PubMed ID: 30609280
[TBL] [Abstract][Full Text] [Related]
80. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
